InMed Pharmaceuticals (NASDAQ:INM) Major Shareholder Buys $10,667.93 in Stock

Posted by Logan Wallace on Oct 18th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 8,021 shares of the stock in a transaction dated Wednesday, October 14th. The stock was bought at an average cost of $1.33 per share, with a total value of $10,667.93. Following the completion of the purchase, the insider owned 954,509 shares in the company, valued at $1,269,496.97. The trade was a 0.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Thursday, October 15th, Adar1 Capital Management, Llc purchased 984 shares of InMed Pharmaceuticals stock. The stock was purchased at an average price of $1.32 per share, for a total transaction of $1,298.88.
On Tuesday, October 13th, Adar1 Capital Management, Llc acquired 564 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.33 per share, for a total transaction of $750.12.
On Thursday, October 8th, Adar1 Capital Management, Llc acquired 2,256 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.33 per share, for a total transaction of $3,000.48.
On Wednesday, October 7th, Adar1 Capital Management, Llc acquired 3,046 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.33 per share, with a total value of $4,051.18.
On Tuesday, October 6th, Adar1 Capital Management, Llc acquired 5,601 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.33 per share, with a total value of $7,449.33.
On Monday, October 5th, Adar1 Capital Management, Llc bought 18,182 shares of InMed Pharmaceuticals stock. The stock was purchased at an average cost of $1.33 per share, with a total value of $24,182.06.
On Friday, October 2nd, Adar1 Capital Management, Llc bought 8,307 shares of InMed Pharmaceuticals stock. The stock was purchased at an average cost of $1.33 per share, with a total value of $11,048.31.
On Thursday, October 1st, Adar1 Capital Management, Llc bought 16,431 shares of InMed Pharmaceuticals stock. The stock was purchased at an average price of $1.33 per share, for a total transaction of $21,853.23.
On Monday, September 14th, Adar1 Capital Management, Llc bought 28,505 shares of InMed Pharmaceuticals stock. The stock was purchased at an average price of $1.29 per share, for a total transaction of $36,771.45.
On Wednesday, September 16th, Adar1 Capital Management, Llc purchased 8,340 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.29 per share, for a total transaction of $10,758.60.

InMed Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ INM opened at $1.32 on Friday. The company’s fifty day moving average is $1.38 and its 200-day moving average is $1.30. The stock has a market cap of $4.37 million, a price-to-earnings ratio of -0.80 and a beta of 0.93. InMed Pharmaceuticals Inc. has a twelve month low of $0.57 and a twelve month high of $2.33.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last announced its quarterly earnings results on Wednesday, September 9th. The company reported ($1.43) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On InMed Pharmaceuticals

An institutional investor recently bought a new stake in InMed Pharmaceuticals stock. Montanova Capital LLC bought a new position in shares of InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $155,000. Montanova Capital LLC owned approximately 3.02% of InMed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 20.12% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, InMed Pharmaceuticals has a consensus rating of “Sell”.

Check Out Our Latest Report on INM

InMed Pharmaceuticals Company Profile

(Get Free Report)

InMed Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of therapies based on rare cannabinoids. The company is developing pharmaceutical candidates intended to address diseases with significant unmet medical needs, using its proprietary IntegraSyn technology to support the production and formulation of cannabinoids.

InMed’s pharmaceutical pipeline has included INM-755, a topical cannabinol-based candidate being investigated for epidermolysis bullosa simplex, a rare genetic skin disorder.